Description

Male Infertility Treatment Market is forecasted to value over USD 5.3 billion by 2027 end and register a CAGR of 4.8% from the forecast period 2021-2027. male infertility refers to the inability of male to cause pregnancy in a fertile woman. A variety of the problems ranging from hormonal disturbances to physical, psychological problems can cause male infertility. Hormonal problems include hyperprolactinemia, hypothyroidism, panhypopituitarism and others. Physical problems include varicocele, torsion, damaged sperm ducts and others. Furthermore, Erectile dysfunction, premature ejaculation and ejaculatory incompetence may lead to male infertility. Although many treatments are available for male infertility, in many cases treatment will not work. In many of the cases, male infertility is caused by testicular damage that leads to the inability of sperm production. In addition, low sperm production and poor sperm quality are also major causes of male infertility. Drugs, hormonal therapy, and assisted reproductive technology make up the global male infertility treatment market (ART). Clomiphene citrate and tamoxifen are two drugs used to treat male infertility. Human chorionic gonadotropin hormone (hCG) and recombinant follicle stimulating hormone (rFSH) are two types of hormone therapy (rFSH). Patients are given gonadotropin treatment to increase their testosterone levels. If these medicines do not work after 6 to 12 months of treatment, assisted reproductive technologies may be a possibility. In vitro fertilization-embryo transfer (IVF-ET), gamete intrafallopian transfer (GIFT), frozen embryo transfer (FET), and zygote intrafallopian transfer (ZIFT) are the several types of assisted reproductive technologies (ZIFT).

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX